StockNews.AI
APVO
StockNews.AI
120 days

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

1. Aptevo plans to sell 2,324,000 shares at $0.862 each. 2. The stock offering may improve liquidity but dilute existing shares.

2m saved
Insight
Article

FAQ

Why Neutral?

Stock offerings typically lead to dilution, affecting share value. Historical examples show mixed impacts on companies post-offering.

How important is it?

The registered direct offering will increase cash but may concern investors about dilution.

Why Short Term?

Short-term impact due to immediate dilution effects; long-term depends on funding use.

Related Companies

ARNANVSMRNA
SEATTLE, WA / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced today that it has entered into definitive securities purchase agreements for the purchase and sale of 2,324,000 shares of the Company's common stock in a registered direct offering (the "offering") at a purchase price of $0.862 per share. The offering is expected to close on or about April 22, 2025 subject to the satisfaction of customary closing conditions.

Related News